FDA Inspection Readiness
|
|
- Sheila Rodgers
- 6 years ago
- Views:
Transcription
1 FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014
2 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection Metrics Final Thoughts References 2
3 Reasons for an Inspection Routinely Assigned Inspections New Product NDAs, PLAs, PMAs, BLAs Assess compliance with regulations Verification of data For Cause Inspections Issues Arising During Application Review Complaints Site termination 3
4 Who/What May Be Inspected? Facilities Personnel Records Systems Policies 4
5 How Are Investigator Sites Selected? Site Performance/Demographics Enrollment Cross-Section (high, moderate, low) Geographic Cross-Section (regional populations) Site Cross-Section (community hospitals, private practices, university hospitals, etc.) Unusual Data Trends Too consistent and uniform Dissimilar data compared to other sites High dropout rate, AE rate, protocol violations 5
6 How Are Investigator Sites Selected? Foreign pivotal trials Study is outside investigator s expertise Complaints Past inspection history 6
7 FDA Inspections May occur with or without prior notice Scheduled (Announced) Inspection typically first inspection, or if previous inspection was nonviolative Unscheduled (Unannounced) Inspection - if prior inspection was violative Duration and frequency at discretion of FDA Start time of inspection is not negotiable Notify FDA of any scheduled extraordinary events such as offsite, all day management meeting, etc. 7
8 What May FDA Review? Protocol/Amendments Investigator s Brochure Informed Consent Forms Correspondence IRB Sponsor FDA Investigational Product Receipt/Storage Dispensing Accountability Quality Systems Laboratory Credentials Form FDA 1572 DOR Log/Site Signature List Monitoring Log CRFs Source Documents Staff Qualifications CVs Training Files/Records Adverse Events/SAEs SOPs Investigator Agreements 8
9 What May FDA Not Review? Financial data not required by 21 CFR Part 54 (Financial Disclosure) Personnel information other than qualifications Studies not covered by the notice of inspection (Form FDA 482) Non-study data and/or records Internal audit reports 9
10 Preparing for an FDA Inspection
11 Getting the Call Establish who should receive calls from FDA Request the following information Nature and scope of the visit Expected arrival (date and time) Number of FDA Investigators coming Anticipated length of stay List of studies/documents they wish to review Notify QA, staff, administrators Notify the sponsor 11
12 Planning Ahead Have Available A Responsible Person to receive Inspector(s) A senior official (President, CEO, COO, Head of QA, etc.) Understands Company Policies Accountability for Facility Operations Legally answerable regarding compliance Accept the Notice of Inspection (Form FDA 482) Identify a point person and a back-up to escort the Inspector(s) and contact other parties as needed 12
13 Planning Ahead Have Available A designated work space for FDA Quiet, comfortable, devoid of confidential information Knowledgeable staff for interviews Company/facility operations Study participation and conduct Company policies Standard Operating Procedures (SOPs) Work Practices 13
14 Begin Document Preparation Study files Regulatory binder(s) List of all studies conducted by PI Protocol number(s) and title(s) IND/IDE number(s) Sponsor(s) Dates of study(ies) 14
15 Begin Document Preparation Investigator agreements Training records Study logs Delegation of Responsibility Monitoring Drug/device accountability Screening/enrollment Protocol deviations SOPs (e.g., table of contents) 15
16 Begin Document Preparation Gather source/supporting documents Ensure they are complete and legible Adequately document exposure to investigational product Adequately document all concomitant medications and AEs Request medical records, if applicable CRFs Completed by authorized staff (see DOR log) Corrections were made appropriately If EDC was used, ensure someone can access ecrfs 16
17 Begin Document Preparation Informed Consent Form All original, fully executed forms (all pages) are present Correct versions(s) were used (IRB approved) Consent was obtained prior to study participation Consenting conducted by an authorized person (see DOR log) Study subjects received copies of ICFs Regulatory binder completeness Drug accountability records Reconcile and corroborate subject dosing/exposure 17
18 Inspection Day
19 Inspection Day Assure that any/all receptionist locations are aware of the procedure: Whom to notify (the order of alternates) when FDA arrives Ask (do not insist) the inspectors to sign-in Ask inspectors to wear visitor badges Do not offer information or answer inappropriate questions Keep the inspection team in the reception area 19
20 Inspection Day The Inspector(s) must present their credentials (identification) Assure this is accomplished for all FDA personnel Do not attempt to photocopy their identification credentials You may write down their names and ID numbers The Inspector(s) must present a signed Notice of Inspection (Form FDA 482) to the highest responsible official available Escort the Inspector(s) to the pre-designated workspace 20
21 Inspection Day Even if you think you know, ask the Inspectors: The reason for the inspection What they will need to see and in what order Normal courtesies may be offered to the Inspectors (e.g., coffee, soft drinks, food, etc.) If the Inspectors want to pay for these, don t disagree. Notify others of FDA presence and location Key areas may be visited during a facility tour (e.g., pharmacy, clinic, laboratory, server room, document storage, etc.) 21
22 Inspection Day Inspector may explain the logistics of the inspection. Afterwards, if it is not clear: Ask inspectors if they plan to meet at the end of each day to review findings If not practical, ask to be briefed of significant findings Ask that the closeout meeting be conducted at a time when RP is available Do not leave FDA unsupervised at any time when reviewing documentation, it is acceptable to leave them in the designated room and check on their progress regularly 22
23 Inspection Day FDA may request a facility tour Always escort the Inspectors when they leave the workspace Predetermine who will participate in the tour Include knowledgeable people who can answer facility questions Make sure designated staff are prepared to answer questions if the tour comes into their area(s) FDA requests for documents Bring in documentation as it is requested by the Inspectors Maintain a log of all documents requested by FDA 23
24 Inspection Day FDA requests for copies of documents Maintain a log of all copies requested by FDA Assign a designated person to make copies Make a duplicate set of all copies requested, one set for you Stamp all requested copies CONFIDENTIAL FDA questions Maintain a log of all questions asked by FDA Predetermine who will address questions on specific subjects If that person is not present, send for him/her 24
25 Responding to FDA Questions The Do s: Be friendly and cooperative Be willing to say I don t know or I can find the answer for you Avoid conditional terms such as usually, typically, generally Stop talking once the question is answered Ask for clarification when needed Control your emotions Maintain eye contact Resist uncomfortable silence 25
26 Responding to FDA Questions The Don ts: Volunteer information that has not been requested Be sarcastic, argumentative, defensive or evasive Guess or hypothesize Point out deficiencies, errors Apologize for issues or deficiencies Express personal opinion Ramble Respond to comments made by FDA 26
27 Affidavits May be prepared by FDA during the inspection A written recount of what took place May be used as a basis for issuance of search and seizure warrants FDA may request executive signatory Never read, review or sign an affidavit Do not sign any generated written statements or inspection recount documents that may constitute an admission of error Do not provide oral confirmation of truthfulness of any statement 27
28 Closeout Meeting At the conclusion of the inspection a closeout meeting will be held Include key operational and management staff Inspectional findings will be presented by FDA If inspectional observations are noted, review each one for clarity and accuracy If you believe an observation is erroneous, discuss why and request the Inspector change it or note the disagreement in their report 28
29 Closeout Meeting A Form FDA 483 may be issued if objectionable findings were discovered If you do not understand a finding, ask for clarity If possible, make corrections before the Inspector leaves and allow him/her to verify (may result in a verified correction annotation on the Form FDA 483) If you agree, and a corrective action (CA) has been identified, explain what will be done and when If you do not yet know what the CA will be, say so Your responses will be included in the Inspector s report 29
30 Closeout Meeting If you disagree with the Form FDA 483 Explain why and discuss with Inspectors (do not argue) Don t promise a CA if you disagree with the observation Your responses will be included in the Inspector s report At the conclusion of the meeting: Thank the Inspector(s) for the time and effort they spent at your site Conduct a debriefing and planning session with inspection participants shortly after the Inspector(s) depart 30
31 Inspection Outcomes
32 After the Inspection - You A written response to all 483 items should be prepared and sent to the issuing FDA office within 10 business days FDA usually allows up to 15 days (be safe, not sorry) The response(s) will then track with the EIR (Establishment Inspection Report) process Enables FDA to consider these responses prior to release of the inspection outcome letter 32
33 After the Inspection - FDA Inspector will write an Establishment Inspection Report (EIR) within 30 days The EIR will be reviewed by the FDA District Office and a classification will be recommended NAI (no action indicated) No objectionable conditions or practices VAI (voluntary action indicated) Objectionable conditions exist; not at threshold to take or recommend administrative or regulatory action OAI (official action indicated) Serious or numerous objectionable conditions found. Regulatory action(s) recommended 33
34 After the Inspection - FDA FDA letter arrives days after inspection: NAI states FDA observed basic compliance with regulations. However, FDA does not always send a letter when no significant deviations were observed. VAI identified deviations that do not meet the threshold of regulatory significance. May require a written response. OAI identifies significant regulatory violations and may result in a Warning Letter or Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) Share letter with senior management and QA 34
35 2013 Inspection Metrics
36 2013 BIMO Inspection Metrics Bioresearch Monitoring Program Conducts inspections of sponsors, clinical investigators, IRBs, animal research facilities, bioanalytical laboratories Inspections in 2013 Clinical Investigator (48%) Bioequivalence (27%) IRBs (12%) Sponsors (9%) GLP (4%) 36
37 2013 BIMO Inspection Metrics Clinical investigator inspections CDER (361; 56%) CBER (91; 14%) CDRH (193; 30%) Clinical investigator inspection outcomes NAI (54%) VAI (43%) OAI (3%) 37
38 2013 BIMO Inspection Metrics Most Prevalent Deficiencies (all investigator inspections) Protocol Deviations 34% Drug Accountability 5% Records 21% Adverse Events 5% Informed Consent 9% IRB Communication 3% 38
39 2013 BIMO Inspection Metrics Most Prevalent Deficiencies (investigator OAI inspections) Protocol Deviations 73% Records 64% Informed Consent 9% Submitting False Information 9% IRB Communication 9% 39
40 Final Thoughts
41 Final Thoughts Be prepared, not scared 41
42 Final Thoughts Document, Document, Document If it wasn t written down, it didn t happen 42
43 Resources International Conference on Harmonization E6 Guideline for Good Clinical Practice FDA Guidance for Industry E6 Good Clinical Practice, Consolidated Guidance FDA Information Sheets nformationsheetsandnotices/ucm htm 43
44 Resources Bioresearch Monitoring Program Compliance Manuals 14.htm 44
45 Thank You!
WIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationHow to Prepare for Federal Inspections and What to Expect
How to Prepare for Federal Inspections and What to Expect Jennifer A. Graf Tufts Medical Center Tufts University Health Sciences Director of IRB Operations Originally presented at the February 2011 Society
More informationInvestigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
More informationBIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
More informationFDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
More informationInspections and Study Monitoring
Inspections and Study Monitoring IRB Education Series 2006 Presentation may only be reused or reprinted with written permission from the Tufts-New England Medical Center/Tufts University IRB office. Audits
More informationSPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS
SPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS Food and Drug Administration Center for Devices and Radiological Health Office of Compliance Division of Bioresearch Monitoring Doreen Kezer,
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationSuccessful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics
Vol. 9, No. 1, January 2013 Happy Trials to You Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics By Swati Tendolkar The United States Food and Drug Administration
More informationAudits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
More informationChapter 48 - Bioresearch Monitoring
COMPLIANCE GUIDANCE MANUAL Chapter 48 - Bioresearch Monitoring Subject SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS Implementation Date February 21, 2001 Completion Date Continuing Product Codes
More informationSolutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationSolutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationGood Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationEssential Documents It s Not Just a Binder!
Essential Documents It s Not Just a Binder! Kelly Unsworth, MS, CCRC, CIP Director of Research Education & Training Office for Human Subject Protection SCORE June 5, 2014 But What percentage of 2014 (to
More informationSession 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationRegulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies
Regulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies DIRECTIONS: 1. The purpose of a regulatory binder is to assure that all essential elements are maintained in an organized
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationSelf-Monitoring Tool
This form is designed for research personnel to use to assess their compliance with TTUHSC El Paso IRB policies and procedures, and federal regulations and guidance governing research with human subjects,
More informationPreparing for and responding to an FDA Inspection Frank Estala Kathy James Clara Vorpahl Anna Taranova
Preparing for and responding to an FDA Inspection Frank Estala Kathy James Clara Vorpahl Anna Taranova Disclosures The speakers have no relevant financial and non-financial relationships to disclose. The
More informationSAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California STANDARD OPERATING PROCEDURES Institutional Review Board Date Effective: April 26, 2001 Index No. R 1217 Date Last Revised: 0 Date
More informationFOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM
FOOD AND DRUG ADMINISTRATION COMPLIANCE PROGRAM GUIDANCE MANUAL PROGRAM 7348.810 CHAPTER 48 Bioresearch Monitoring SUBJECT: SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS REVISION: IMPLEMENTATION
More informationInitially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees
Location: Los Angeles Research Institute: Los Angeles, CA Investigation Product/Test Article: Laftr Visit Mechanism: On-site Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009
More informationCLOSE OUT VISIT REPORT (NO CRF TO MONITOR)
Date: Page: 1 of 8 CLOSE OUT VISIT REPORT (NO CRF TO MONITOR) Protocol: PI Name: PI Address: Date of Visit: Monitor(s): Other Sponsor Personnel Present: Site Personnel Present at Visit (include names and
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)
Replaces previous version 203.01: 01 July 2014 Study Start-Up SS 203.01 STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature
More information4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.
SOP #: MON-101 Page: 1 of 6 1. POLICY STATEMENT: The DF/HCC understands that external sponsors are required to monitor the progress of clinical investigations and ensure appropriate research data collection
More informationChecklist prior to recruiting first patient
Pre-Site selection Site Initiation Visit (SIV) What kind of questions should you ask How you should prepare for this visit Delegation logs Training logs ECRF/CRF Checklist prior to recruiting first patient
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationFDA Medical Device Regulations vs. ISO 14155
Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationLocal VA VA ORD CSP Other VA ORD. IRB of Record Registration Number: IRB Operated by: Local VA Non-local VA Academic Affiliate VHA Central IRB
ADMINISTRATIVE INFORMATION Principal Investigator: Study Coordinator: Protocol Title: Current Audit Date: Research Compliance Officer (RCO) or Designated Auditor(s): Local VA VA ORD CSP Other VA ORD Sponsor
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationSite Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG
Site Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG INFORMATION AND GUIDANCE SHEET FOR THE COMPLETION OF THE SITE SIGNATURE AND
More informationClinical Trial Quality Assurance Common Findings
Clinical Trial Quality Assurance Common Findings Objectives Identify common findings found in research study reviews conducted by the CTQA Program Understand what findings require an action plan vs. a
More informationStudy Management PP STANDARD OPERATING PROCEDURE FOR Safeguarding Protected Health Information
PP-501.00 SOP For Safeguarding Protected Health Information Effective date of version: 01 April 2012 Study Management PP 501.00 STANDARD OPERATING PROCEDURE FOR Safeguarding Protected Health Information
More informationFDA Perspective on the Pre- Submission Program: Updates from MDUFA IV
FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV Maureen Dreher, PhD Policy Analyst Clinical Trials Program/ Office of Device Evaluation/ CDRH Agenda Pre-Submission Program background
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More informationGood Documentation Practices. Human Subject Research. for
Good Documentation Practices for Human Subject Research Bridget M. Psicihulis, RHIA, CCRC Quality Improvement Unit Coordinator Human Research Protection Program Wheaton Franciscan Healthcare (last updated
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting
Study Management SM 306.00 STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick M. Schnell, MD,
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationTomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
More informationPLATELET-ORIENTED INHIBITION ISCHEMIC STROKE (POINT) MONITORING PLAN IN NEW TIA AND MINOR. Version 2.0 Updated 11 May 2017
PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) MONITORING PLAN Version 2.0 Updated 11 May 2017 Monitoring Plan Table of Contents 1.0 Introduction... 4 2.0 Purpose... 4 3.0 Review
More informationONADE s Data Quality Review
ONADE s Data Quality Review Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulatory Affairs in Animal Health Seminar Kansas State University Olathe March 06, 2018 Presenter: Ana
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationPreparing for Audits and Post Approval Monitoring April 29, 2015
Preparing for Audits and Post Approval Monitoring April 29, 2015 Presented By: Piper Hawkins Green, CIP Olga Jonas, CIP IRB Compliance Analyst IRB Compliance Analyst Presentation Agenda Regulatory background
More informationQUALITY ASSURANCE PROGRAM
QUALITY ASSURANCE PROGRAM Elaine Armstrong, MS Quality Assurance Manager PURPOSE Verify accuracy of submitted data Verify compliance with protocol and regulatory requirements Provide educational support
More informationSARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY
PS1006 SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY TITLE: Satellite Site Management Plan Job Title of Reviewer: POLICY #: EFFECTIVE DATE: REVISED DATE: POLICY TYPE: Elizabeth Carr, R.N.,
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationMastering Clinical Research April 19, :30 am
Mastering Clinical Research April 19, 2017 7:30 am New Question and Answer Response System Log In Directions Use the following link to access pre and post test questions: http://www.socrative.com/ Click
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More information11/18/2016. UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities SESSION 4
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH
SOP #: CON-100 Page: 1 of 9 Effective Date: 2/28/17 1. POLICY STATEMENT: The research team is responsible for obtaining and documenting the informed consent of each subject who participates in research.
More informationThe SOP applies to all human subject research falling under the purview of the University of Missouri Institutional Review Board.
Institutional Review Board.... University of Missouri-Columbia.. Standard Operating Procedure Informed Consent Types and Elements Informed Consent Types and Elements Effective Date: December 12, 2005 Original
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Husain, Mustafa M, M.D. 23-Jul-08 Department of Health and Human Services Public Health Service Food and Drug Administration Center for
More informationThe Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.
The Clinical Research Center Research Practice Manual Guideline for Study Document and Data Handling RPG-08 Purpose Guideline This Guideline provides functional definitions for common data management terms;
More informationDEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER
DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice Food and Drug Administration 9200 CCorporate Bl%d. RockOlc MD 20550 WARNING LETTER VIA FEDERAL EXPRESS MP 4 2007 William D. Tobler, MD Mayfield
More informationStudy Initiation Meeting
Puerto Rico Clinical and Translational Research Consortium Study Initiation Meeting I. Procedure Title: Study Initiation Meeting II. Overview/Procedure Description: 1. The Clinical Research Resources and
More information: study utilizing trieib)(4) b)(4) I I""-", _
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EXPRESS Sarah H. Lisanby, M.D. 1051
More informationSOP : Quality Assurance Inspections SCOPE RESPONSIBILITIES. APPROVAL AUTHORITY EFFECTIVE DATE May PURPOSE 2.
TITLE SCOPE RESPONSIBILITIES APPROVAL AUTHORITY EFFECTIVE DATE May 2018 901: Quality Assurance Inspections All research submitted to the University of British Columbia s Research Ethics Boards The Vice
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
More informationAN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES
1 AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES Key Clinical Study Tasks and Activities 2 Discussion of Key Tasks and Activities 3 Development of the Clinical Protocol and Study Materials 3 Qualification
More informationWARNING LETTER VIA FEDERAL EXPRES S
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EPRES S George W. LeMaitre Chairman
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationGCP: Investigator Responsibilities. Susan Tebbs Nicola Kaganson
GCP: Investigator Responsibilities Susan Tebbs Nicola Kaganson Investigator Responsibilities Qualifications & agreements Resources Responsibilities to the subject Ethics The protocol The IMP & randomisation
More informationRegulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
More informationComprehensive Protocol Feasibility Questionnaire
Protocol Title: Potential Principal Investigator: Regulatory Coordinators: Department Chair: PROJECT FEASIBILITY PI and Study Team: YOUR RESPONSES TO THIS SURVEY CONSTITUTE A BEST ESTIMATE OF RESOURCES
More informationInvestigator Site File Standard Operating Procedure (SOP)
Investigator Site File Standard Operating Procedure (SOP) DOCUMENT CONTROL: Version: 1 Ratified by: Quality and Safety Sub Committee Date ratified: 30 January 2017 Name of originator/author: Research Nurse
More informationOverview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.
Overview of the IMB s Approach to Inspection of Good Clinical Practice GCP Seminar Dublin, 27 th January 2010 Deirdre O Regan GCP/Pharmacovigilance Inspection Manager Slide 1 Introductions/Organisation
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationSAMPLE - Medical Staff Credentialing and Initial Appointment Policy
Subject: Medical Staff Credentialing and Initial Appointment Number: Effective Date: Supersedes SPP# Dated: Approved by: (signature) Distribution: Medical Staff, Credentialing Manual, Medical Staff Office
More information16 STUDY OVERSIGHT Clinical Quality Management Plans
16 STUDY OVERSIGHT... 1 16.1 Clinical Quality Management Plans... 1 16.2 Site Visits by the LOC, SDMC and LC... 2 16.3 Protocol Team Oversight... 3 16.4 Oversight of Reportable Protocol Deviations... 3
More informationCenter for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
More informationSTUDY TEAM RESPONSIBILITIES ORIENTATION FOR NEW CLINICAL RESEARCH PERSONNEL MODULE 2
ORIENTATION FOR NEW CLINICAL RESEARCH PERSONNEL MODULE 2 Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationRegulatory Inspections
Regulatory Inspections An Overview of Process, Observations, and Guidance for Investigators Alison Urton, Group Administrator Clive Hansen, Audit Team Leader Outline Regulatory History Health Canada Overview
More informationWARNING LETTER. an both of which were sponsored by. (formerly ). The products
g5~5s c Public Health Service ' SLRV7CLS r r f+ ~1Mr~la DEPARTMENT OF HEALTH & HUMAN SERVICES DEC 2 1 2005 Food and Drug Administration 9200 Corporate Blvd. Rockville, Maryland 20850 WARNING LETTER Via
More informationCourse program. Good Clinical Practice (GCP) course for surgeons
Course program Good Clinical Practice (GCP) course for surgeons 2 Good Clinical Practice (GCP) course for surgeons 7 Principles of Education Based on needs Relevant Interactive Leads to verifiable outcomes
More informationClinical Research Professionals
Training & Resources for Clinical Research Professionals Course & Publications Catalog January July 2016 In-Person and Web-Based Training Courses, Customized Training, elearning and Publications for Clinical
More informationSection 9. Study Product Considerations for Non- Pharmacy Staff
Section 9. Study Product Considerations for Non- Pharmacy Staff Table of Contents 9.1 Dispensing Study Product 9.1.1 Chain of Custody 9.1.2 Initial Vaginal Ring Dispensing(s)- Prescription Overview 9.2
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
60-4 (v4 ( ~' DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service. Food and Drug Administration 9200 Corporate Boulevard el Rockville, Maryland 20850 MAY - 6 2008 VIA FEDERAL EXPRES S Merrill W.
More informationETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM
ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationClinical Trial Readiness Checklist October 2014
The clinical trial readiness checklist is a tool which can help new and experienced researchers prepare for upcoming clinical studies. It is designed to be a quick reference to ensure that you have the
More information